Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies - Wikidata - awgldk - TriplyDB

Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies

Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies

http://www.wikidata.org/entity/Q28236293

about

Clinical management of sleep disturbances in Alzheimer's disease: current and emerging strategies The overlap between anxiety, depression, and obsessive-compulsive disorder.Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics Effect of Light and Melatonin and Other Melatonin Receptor Agonists on Human Circadian Physiology A systematic review of agomelatine-induced liver injury Agomelatine in the treatment of major depressive disorder: an assessment of benefits and risks Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression Agomelatine in the treatment of mild-to-moderate depression in patients with cardiovascular disease: results of the national multicenter observational study PULSE A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or ag Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders.Combination of agomelatine and bupropion for treatment-resistant depression: results from a chart review study including a matched control group.Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder Agomelatine and migraine management: a successfully treated case series.Conflicts of interest in nutritional sciences: The forgotten bias in meta-analysis.Pharmacological and non-pharmacological treatments for major depressive disorder: review of systematic reviews.Agomelatine Increases BDNF Serum Levels in Depressed Patients in Correlation with the Improvement of Depressive Symptoms.The chronic mild stress (CMS) model of depression: History, evaluation and usage Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines.Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder.Principles in the Evaluation of Systematic Reviews.Therapeutic strategies for circadian rhythm and sleep disturbances in Huntington disease.Potential pleiotropic beneficial effects of adjuvant melatonergic treatment in posttraumatic stress disorder.An Update on the Use of Sedative-Hypnotic Medications in Psychiatric Disorders.Inflammation and the Silent Sequelae of Stroke.Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients.The Psychiatric Inclusion and Exclusion Criteria in Placebo-Controlled Monotherapy Trials of Bipolar Depression: An Analysis of Studies of the Past 20 Years.Inclusion/exclusion criteria in late life depression antidepressant efficacy trials.Pooled Analysis of Four Non-Interventional Studies: Effectiveness and Tolerability of the Antidepressant Agomelatine in Daily Practice.The Isoxazole Ring and Its N-Oxide: A Privileged Core Structure in Neuropsychiatric Therapeutics.Does melatonin treatment change emotional processing? Implications for understanding the antidepressant mechanism of agomelatine.Agomelatine or ramelteon as treatment adjuncts in glioblastoma and other M1- or M2-expressing cancers.Activation of Melatonin Receptors Reduces Relapse-Like Alcohol Consumption.Marine cyanobacteria-derived serotonin receptor 2C active fraction induces psychoactive behavioral effects in mice Animal models of addiction.Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open-label, real-world study.Disturbances of diurnal phase markers, behavior, and clock genes in a rat model of depression; modulatory effects of agomelatine treatment.Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder.Agomelatine, venlafaxine, and running exercise effectively prevent anxiety- and depression-like behaviors and memory impairment in restraint stressed rats.The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine.Mitochondrial Agents for Bipolar Disorder.

P2860

Q26772851-67B92ECC-B109-437F-BB7B-0791ECAAAE37 Q26781117-ACD02D99-C77A-4ABC-AD01-51125F0C41FD Q26782997-84EAACA7-AA91-4899-8553-3CAD4BC59E09 Q28394033-25C20FBF-9DF2-442A-AE7A-37ED34DBFDEF Q28648515-ECFEA6D6-9BBD-4E36-8A4B-5313D20F15AB Q28651497-5E239EC4-294F-4D46-8490-1EFBDBD97798 Q28651498-CB5BFABF-FB90-44D9-AC31-4C15C24933C3 Q33610031-44D4026D-7CCC-44F4-8EEF-ADBB74AA72BA Q34041642-670BCA31-F869-430D-9005-BD947C840539 Q34358480-3E5D2A9D-6030-40C8-BE3A-E43545621C9E Q35169141-22CB4191-EE1E-4420-A4C3-B0A25EF68E07 Q35536869-6EBD6A43-8C40-4210-9F47-83A0F36937F4 Q35948842-D04A8E97-C945-4FDE-AF4F-2CDCA4059112 Q36391292-0E91E983-F6E3-4C35-B388-F2BC338CE03D Q36405731-13388275-6FAF-4ED1-8950-7233D7ECEB33 Q36950592-8169E4F2-D7B6-45B6-931A-99F8D2ABEEBB Q37648894-2EDED5D9-75AE-4B60-809A-AD3973C41891 Q38476909-465F07EA-2065-4C27-9650-B8524A952B13 Q38506798-0B30516D-406D-45B6-953B-2E8292D44208 Q38644827-A8C44DAD-762F-423F-900D-9CD57DD70BA5 Q38654045-39757D64-FF8A-4D09-BF33-CC8AAD641BED Q38803216-39168B9A-F659-44A7-860C-4CE3A59DD24A Q38841819-DC725A4D-7D05-4BA2-937A-616BB5E2768C Q38871034-630B556B-59CC-4405-874E-C53519B1C791 Q38876395-3B4BA9D0-024C-4A68-821F-538F4AF9D609 Q38931913-80368038-68E8-45B2-BEF7-8C2489DE83DC Q38933448-1AB92EB9-2ACC-49BC-A4CF-FB58E6E9B3D2 Q38953673-F50E61D3-0755-4105-909D-A79BF7624E0C Q39157903-A8EB75C3-D15B-4310-B4B4-3F5C4E803DCE Q40737578-E4ADD330-AEA9-48CB-9A42-FCC3892101B9 Q41103172-A7226D22-EDE3-4C2D-9E58-2634F8500229 Q41449637-A1DDD16B-4BCA-4D3D-9B14-8FEA9A6E1411 Q42861391-159CE424-27BE-46CD-AB1A-EE0A7947D581 Q47156600-5A0E2B4C-4AF7-408D-B24A-FA4BA8959859 Q47371574-0802AE36-6C71-4145-82BD-E548BC7B7DF5 Q47389458-EC921368-71C9-44E2-9983-C9F4AF752664 Q47657288-2D589E70-27CB-4BE5-BFD1-C724497089D3 Q47720596-9077EC3E-8224-4098-9D6C-74BDF0FCBE96 Q47950300-1825D022-95D3-4BCF-88B0-08DEFD7C4228 Q52621890-E03A873B-4769-4797-92D7-4899B8F2AB3C

P2860

Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies

http://www.wikidata.org/entity/Q28236293

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Antidepressant efficacy of ago ...... lished and unpublished studies

@ast

Antidepressant efficacy of ago ...... lished and unpublished studies

@en

Antidepressant efficacy of ago ...... lished and unpublished studies

@nl

type

label

Antidepressant efficacy of ago ...... lished and unpublished studies

@ast

Antidepressant efficacy of ago ...... lished and unpublished studies

@en

Antidepressant efficacy of ago ...... lished and unpublished studies

@nl

prefLabel

Antidepressant efficacy of ago ...... lished and unpublished studies

@ast

Antidepressant efficacy of ago ...... lished and unpublished studies

@en

Antidepressant efficacy of ago ...... lished and unpublished studies

@nl

P1433

Q28236293-B25CB2C6-E6A1-4703-8DCB-CFD8750F3806

P1476

Q28236293-E0A4C00D-658F-4F4D-905A-797BDA262DAE

P2093

Q28236293-038CAEE4-AB2E-42EA-B882-5F1FA566F92E

Q28236293-22205780-5E67-4400-9BC4-2488D8493AD9

Q28236293-C136C8D9-799B-4F85-ABC6-8C8005AE3F46

P275

Q28236293-86380F24-9541-4AE2-80A2-59574BF8E3E4

P2860

Q28236293-00626C59-8108-4BF3-A7E7-F71BA040AD61

Q28236293-05C75364-FCCE-4AB1-AE6F-744E5F3BBE6F

Q28236293-06D154E0-344E-41BF-8C7C-E386B4026620

Q28236293-0D678402-8D94-44E2-800F-5709065D0857

Q28236293-113F783C-4B04-4E72-BB51-7FDD17B14423

Q28236293-1278B0EC-BB03-4960-8C86-BAF48E70BBC8

Q28236293-23B97347-4F9D-4445-A971-A1EB3B6F9FCA

Q28236293-274426DA-B082-412B-A4D2-FAE587693773

Q28236293-29CA4830-BB19-4FA9-92E2-6D532C1DAC0A

Q28236293-2DA2DC3F-EE50-45DE-8CF8-A7B46B05B5C5

P304

Q28236293-27D5204C-1294-45B4-8EE5-F1DDBA913067

P31

Q28236293-1F35FCCC-BE2D-4682-8FA7-7D4D908CC912

Q28236293-76E98E79-BD98-4CBA-9E3A-74C9F1C2FE15

Q28236293-E1F68EA7-C2B3-472D-AC17-AE8A284FFDFA

P356

Q28236293-AD4D0447-4A6D-4463-9D88-D6BFAA1D01F5

P407

Q28236293-327C4069-7B3D-4326-B774-8A341DC85F6A

P433

Q28236293-9D636199-E760-4ACF-9A26-B3F9BCD8E587

P478

Q28236293-AA6C0998-FB1D-41D2-BC68-4497E1685023

P50

Q28236293-7A1403B8-DD85-4EE7-BED8-4D9CAC6F67DF

P577

Q28236293-B20F08C2-E13E-40F0-ACD3-792C8FC2CA22

P5875

Q28236293-49435B0D-F51C-4B68-AA90-DAC9D05E2ACA

P698

Q28236293-6F65B4F0-5F70-4135-8E8C-F93BF982A1E6

P921

Q28236293-405D7504-5DCC-47F4-B9D9-20CBE7B7F416

Q28236293-8FD88FA2-5B86-4613-B212-FB6F8150266F

Q28236293-9B24811D-0373-4D9C-8432-8173F2F6FD88

Q28236293-ADD306B0-F38A-4FB5-AE39-CDA4DA1631D8

P932

Q28236293-574D2909-0BC3-412C-A410-B58C0C5ED666

P356

P1433

P1476

Antidepressant efficacy of ago ...... lished and unpublished studies

@en

P2093

Anna Sparshatt

http://www.w3.org/2001/XMLSchema#string

Olubanke Olofinjana

http://www.w3.org/2001/XMLSchema#string

Seema Varma

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 3.0 Unported

P2860

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

Antidepressants and Body Weight

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

Mirtazapine versus other antidepressive agents for depression

A rating scale for depression

Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials

Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal

Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine

P304

g1888

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.G1888

http://www.w3.org/2001/XMLSchema#string

P407

P433

mar19 5

http://www.w3.org/2001/XMLSchema#string

P478

348

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260950115

http://www.w3.org/2001/XMLSchema#string

P698

24647162

http://www.w3.org/2001/XMLSchema#string

P921

carboxylic acid

mental depression

P932

3959623

http://www.w3.org/2001/XMLSchema#string